Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 17/20 | 0.65 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | CCR9 | P51686 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8687383 | 0.88 | CCR2 (0.62) | CCR2ABCB11CCR9 | |
| SCHEMBL4372812 | 0.85 | CCR2 (0.60) | CCR2ABCB11 | |
| SCHEMBL6964777 | 0.85 | CCR2 (0.49) | CCR2GPR35 | |
| SCHEMBL22003789 | 0.84 | ACLY (0.51) | CCR2GPR35 | |
| SCHEMBL9613337 | 0.83 | GPR35 (0.62) | CCR2GPR35CCR9 | |
| SCHEMBL1553069 | 0.83 | GPR35 (0.67) | CCR2GPR35ABCB11 | |
| SCHEMBL8689838 | 0.82 | ALDH1A1 (0.54) | CCR2 | |
| SCHEMBL7681730 | 0.82 | TDP1 (0.61) | CCR2ABCB11 | |
| SCHEMBL27658570 | 0.82 | CCR2 (0.82) | CCR2GPR35ABCB11CCR9 | |
| SCHEMBL4537478 | 0.81 | CCR2 (0.81) | CCR2GPR35ABCB11CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | claimed |
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2021083998-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-06 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10577356-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190040045-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2019-02-07 | — | — | US | disclosed |
| US-10118914-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3131905-B1 | SPIRO UREA COMPOUNDS AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-28 | — | — | EP | disclosed |
| US-9738652-B2 | Spiro urea compounds as RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-22 | — | — | US | disclosed |
| US-20170166554-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2010065310-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-7534809-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1799696-B1 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1961757-A1 | Phosphoindoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1799696-A2 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006054182-A2 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS LLC | 2006-04-06 | — | — | US | disclosed |
| US-5852046-A | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0639573-A1 | Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | CCR2 4510/4885GPR35 3726/4885ABCB11 390/4885 |
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDO1, PPP5C, INMT | CCR2 2409/4885GPR35 3285/4885ABCB11 4033/4885 |
| US-20170166554-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | CNR1, CNR2, ARRB1 | CCR2 81/4885GPR35 27/4885ABCB11 3181/4885 |
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | HTR3C, MECP2, CDK2 | CCR2 501/4885GPR35 4320/4885ABCB11 4880/4885 |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | CCR2 4191/4885GPR35 1008/4885ABCB11 1453/4885 |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDO1, PPP5C, INMT | CCR2 2409/4885GPR35 3285/4885ABCB11 4033/4885 |
| US-10577356-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | CNR1, CNR2, ARRB1 | CCR2 81/4885GPR35 27/4885ABCB11 3181/4885 |
| US-10118914-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | CNR1, CNR2, ARRB1 | CCR2 81/4885GPR35 27/4885ABCB11 3181/4885 |
| US-20190040045-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | CNR1, CNR2, ARRB1 | CCR2 81/4885GPR35 27/4885ABCB11 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.